Pomerantz LLP is investigating potential securities claims on behalf of Fulgent Genetics, Inc. investors and advises affected shareholders to contact the firm. The March 3, 2026 alert is part of a broader same‑day batch of Pomerantz notices — including an investigation of Novo Nordisk — suggesting coordinated outreach to investors across several issuers.
Click a connection line between nodes to view confidence and evidence.